Durable complete leptomeningeal and intracerebral responses to first-line Pembrolizumab in highly-selected Non-small cell lung cancer patients

Durable complete leptomeningeal and intracerebral responses to first-line Pembrolizumab in highly-selected Non-small cell lung cancer patients

Intracranial metastases occur in 30–50% of patients with Non-small cell lung cancer (NSCLC) and have a poor prognosis despite current therapies utilising systemic chemotherapy, neurosurgery and radiotherapy. In contrast to the robust evidence for using immunotherapy to treat intracranial metastases...

Full description

Bibliographic Details
Main Authors: Yi Tong Vincent Aw, Geoffrey David Peters
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Non-small cell lung cancer
Pembrolizumab
Immunotherapy
Intracranial response
Leptomeningeal disease
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621922000734

Internet

http://www.sciencedirect.com/science/article/pii/S2666621922000734

Similar Items